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Oxidative stress and inflammation, leading to endothelial dysfunction, contribute to the pathogenesis of atherosclerosis. The
popularity of natural product supplements has increased in recent years, especially those with purported anti-inflammatory
and/or antioxidant effects. The efficacy and mechanism of many of these products are not yet well understood. In this study, we
tested the antioxidant and anti-inflammatory effects of a supplement, HIPER Health Supplement (HIPER), on cytokine-induced
inflammation and oxidative stress in human coronary artery endothelial cells (HCAECs). HIPER is a mixture of French maritime
pine bark extract (PBE), honey, aloe vera, and papaya extract. Treatment for 24 hours with HIPER reduced TNF-𝛼-induced reactive
oxygen species (ROS) generation that was associated with decreased NADPH oxidase 4 and increased superoxide dismutase-
1 expression. HIPER inhibited TNF-𝛼 induced monocyte adhesion to HCAECs that was in keeping with decreased expression
of vascular cell adhesion molecule-1 and intercellular cell adhesion molecule-1 and decreased nuclear factor-kappa B (NF-𝜅B)
activation. Further investigation of mechanism showed HIPER reduced TNF-𝛼 induced I𝜅B𝛼 and p38 and MEK1/2 MAP kinases
phosphorylation. Our findings show that HIPER has potent inhibitory effects on HCAECs inflammatory and oxidative stress
responses that may protect against endothelial dysfunction that underlies early atherosclerotic lesion formation.
1. Introduction
Chronic subacute inflammation and oxidative stress leading
to endothelial dysfunction underlie the early pathogenesis
of atherosclerosis [1, 2]. A key early step in atheroscle-
rotic lesion formation is the adhesion of monocytes to the
endothelium and the subsequent migration of the mono-
cytes into the subintima where they engulf oxidized LDL
and become classical “foam cells” [3]. The interaction of
monocytes with endothelial cells is mediated by cell adhesion
molecules, the most important of which are vascular cell
adhesion molecule-1 (VCAM-1) and intercellular cell adhe-
sion molecule-1 (ICAM-1) expressed by the endothelial cells
[4].The expression of bothVCAM-1 and ICAM-1 is regulated
by nuclear factor-kappa B (NF-𝜅B), a transcription factor that
is activated by oxidative stress.
Inflammation and oxidative stress are considered key
targets to improving or reversing endothelial dysfunction
associated with early atherosclerotic plaque formation [1,
2]. In addition to main stream medical treatments, there
is increasing popularity in using natural compounds for
their intrinsic anti-inflammatory and antioxidant properties.
HIPER Health Supplement (HIPER) was formulated using
a combination of French maritime pine bark extract (Pinus
pinaster, PBE), aloe vera, honey, and papain. For PBE, aloe
vera, and honey, there is existing scientific literature sup-
porting either anti-inflammatory or antioxidant properties
[5–9]. In this study, we have investigated whether HIPER,
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a combination of these ingredients, could protect human
coronary artery endothelial cells (HCAECs) from cytokine-
induced inflammatory and oxidative stress responses. Our
findings show that HIPER was effective in suppressing
VCAM-1 and ICAM-1 expression, primarily via its effect on
decreasing NF-𝜅B and MAP kinase activation. This anti-
inflammatory effect is most likely due to the effect of HIPER
on lowering intracellular ROS levels.
2. Materials and Methods
2.1. HIPER Health Supplement. HIPER Health Supplement,
as well as the individual components of aloe vera, honey,
papain, and PBE, was kindly donated by Plasmaide Pty
Ltd. (Sydney, NSW, Australia). The supplement was filtered
through a 0.22𝜇m pore size sterile syringe filter unit before
use (MerckMillipore, Bayswater, VIC, Australia). HIPERwas
used at a volume of 25 𝜇L or 50𝜇L per mL of media that
equated to a 50mL or 100mL dose recommended for human
consumption.
2.2. Cell Culture. HCAECs (Cell Applications, San Diego,
CA, USA) were cultured in MesoEndo Cell Growth Medium
(Cell Applications). HCAECs were pretreated with HIPER
for 3 h at a dose of 6.25, 12.5, 25, or 50 𝜇L per mL of media
or phosphate-buffered saline (PBS; Astral Scientific, Sydney,
NSW, Australia) as vehicle-control and then stimulated with
TNF-𝛼 (1–5 ng/mL) (Sigma-Aldrich, Castle Hill, NSW, Aus-
tralia) for 1 h.
2.3. RT-qPCR. Total RNA was extracted using TRI reagent
(Sigma-Aldrich) and the concentration was normalized
to 100 ng/𝜇L using a NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific, Mulgrave, VIC, Australia). cDNA
was generated from 100 ng of total RNA using iSCRIPT
(Bio-Rad, Regents Park, NSW, Australia). An aliquot of each
cDNA sample (1 𝜇L) was amplified by qPCR in reaction
mixtures containing primers (12 pmol each) and iQ SYBR
Green Supermix (Bio-Rad). Sequences of the primers used in
the qPCR reactionwere as follows: humanNOX4 forward: 5󸀠-
GTGGTGGTGCTATTCCTCAT-3󸀠, reverse: 5󸀠-GCTGGT-
TCGGTTAAGACTGA-3󸀠; human SOD-1 forward: 5󸀠-GCG-
AGTTATGGCGACGAA-3󸀠, reverse: 5󸀠-CAGTCAGTC-
CTTTAATGCTTCC-3󸀠; human VCAM-1 forward: 5󸀠-ATG-
TAGTGTCATGGGCTGTG-3󸀠, reverse: 5󸀠-GGAATGAGT-
AGAGCTCCACC-3󸀠; human ICAM-1 forward: 5󸀠-CCA-
TCTACAGCTTTCCGGCGC-3󸀠, reverse: 5󸀠-CTCTGG-
GGTGGCCTTCAGCA-3󸀠; human 𝛽2-microglobulin (B
2
M)
forward: 5󸀠-CATCCAGCGTACTCCAAAGA, reverse: 5󸀠-
GACAAGTCTGAATGCTCCAC; and human GAPDH for-
ward: 5󸀠-CGATGCTGGCGCTGAGTACGT-3󸀠, reverse: 5󸀠-
CCTGCAAATGAGCCCCAGCCTTC-3󸀠. Amplification was
performed in a BioRad iQ5 thermocycler (Bio-Rad) using the
following protocol: 95∘C for 30 sec, Tm of specific primer sets
for 30 sec, and 72∘C for 30 sec. Relative changes in mRNA
levels were determined by the ΔΔCT method [10], using
human B
2
M and GAPDH as the reference genes.
2.4. Monocyte Adhesion Assay. HCAECs were pretreated
with HIPER (25𝜇L/mL) for 3 h before treated with TNF-
𝛼 (1 ng/mL) for a further 3 h. After treatment, monocyte to
endothelial cell adhesion assays were performed as previously
described [11].
2.5. Enzyme-Linked Immunosorbent Assay (ELISA).
HCAECs were plated in 96-well plates and pretreated with
HIPER (25 𝜇L/mL) and for the MAP kinase experiments,
either p38 MAP kinase inhibitor SB203580 (Calbiochem/
EMD Chemicals Inc., Gibbstown, NJ, USA) or MEK1/2
inhibitor UO126 (Calbiochem/EMD Chemicals Inc.) for
3 h. All cells were then treated with TNF-𝛼 (1 ng/mL) for
a further 3 h. After treatment, ELISA was performed as
previously described for VCAM-1 and ICAM-1 [11]. I𝜅B𝛼
levels were measured by FunctionELISA I𝜅B𝛼 (Active Motif,
Carlsbad, CA, USA). p38 MAP kinase levels were measured
by human/mouse phospho-p38 MAP kinase (T180/Y182)
immunoassay (R&D Systems Inc., Minneapolis, MN, USA).
MEK1/2 levels were measured by the commercially available
FACE MEK1/2 ELISA kit (Active Motif).
2.6. NF-𝜅B Nuclear Translocation Assay. HCAECs were
exposed to HIPER (25𝜇L/mL) for 3 h and then stimulated
with TNF-𝛼 (1 ng/mL) for 3 h. After treatment, nuclear pro-
teins were extracted using the NucBuster protein extraction
kit (Merck Millipore) and nuclear NF-𝜅B levels were then
determined as previously described [12].
2.7. Measurement of Intracellular Reactive Oxygen Species
(ROS). Intracellular ROS levels were measured using the
DCF assay (Thermo Fisher Scientific). HCAECs were pre-
treated with HIPER (25 or 50 𝜇L/mL) for 3 h before stimu-
lation with TNF-𝛼 (5 ng/mL) for a further 3 h. After treat-
ment, media were removed and cells washed with 1x PBS.
H
2
DCFDA stain (Thermo Fisher Scientific) was diluted in
1x PBS to a concentration of 10 𝜇M before treatment of cells.
The cells were incubated at 37∘C for 12min before washing
with 1x PBS and ROS level was determined by fluorescence
measurement (485 nm/535 nm).
2.8. Statistical Analysis. All data are expressed as mean ±
SEM. Differences between conditions were determined by
one-way ANOVA with Bonferroni’s post hoc test analysis
(GraphPad PRISM Software Version 4.03). Significance was
set at 𝑃 < 0.05.
3. Results
3.1. HIPER Suppressed TNF-𝛼-Induced ROS Levels in
HCAECs. TNF-𝛼 treatment of HCAECs increased ROS
levels (Figure 1). Pretreatment with HIPER abrogated the
TNF-𝛼 effect in a dose-dependent manner (𝑃 < 0.05).
3.2. HIPER Modulated the Expression of Enzymes Involved
in the Oxidative Stress Response. TNF-𝛼 treatment increased
NADPH oxidase 4 (NOX4) expression by 15%, a result that
was abrogated in HCAECs pretreated with 25 or 50 𝜇L/mL


























Figure 1: HIPER reduced ROS levels in TNF-𝛼-activated HCAECs.
HCAECs were treated with HIPER at doses of 25 or 50𝜇L/mL for
3 h before activation with 5 ng/mL TNF-𝛼 for 3 h. ROS levels were
measured using the DCF assay. Data are shown as mean ± SEM (𝑛 =
3). #𝑃 < 0.05 versus control, ∗𝑃 < 0.05 versus TNF-𝛼.
HIPER for 3 h (Figure 2(a); 𝑃 < 0.05). In contrast, TNF-
𝛼 decreased superoxide dismutase-1 (SOD-1) expression by
24% (Figure 2(b); 𝑃 < 0.05), which was also abrogated by
HIPER pretreatment at both the 25 and 50 𝜇L/mL concen-
trations (𝑃 < 0.05).
3.3. HIPER Suppressed TNF-𝛼-Induced VCAM-1 and ICAM-
1 Expression and Monocyte Adhesion to HCAECs. HCAECs
were pretreated with HIPER (25𝜇L/mL) and then stimulated
with TNF-𝛼. Figures 3(a) and 3(b) show that therewas a dose-
dependent decrease in ICAM-1 (a) and VCAM-1 (b) mRNA
levels in response to HIPER. The decrease in mRNA levels
correlated with a decrease in protein as measured by ELISA
where HIPER (25 𝜇L/mL) reduced ICAM-1 protein levels by
25% (Figure 3(c); 𝑃 < 0.05) and VCAM-1 protein levels by
18% (Figure 3(d); 𝑃 < 0.5).
Figure 4 shows that TNF-𝛼 stimulated monocyte adhe-
sion to HCAECs by 8.5-fold (𝑃 < 0.05). Pretreatment
of HCAECs with HIPER (25𝜇L/mL) suppressed TNF-𝛼-
stimulated monocyte adhesion by 2-fold (𝑃 < 0.05).
3.4. HIPER Suppressed TNF-𝛼-Stimulated NF-𝜅B Activa-
tion. Given that HIPER suppressed TNF-𝛼-induced ROS
levels and VCAM-1 and ICAM-1 expression, it was next
explored whether HIPER suppressed TNF-𝛼-induced NF-
𝜅B activation. In its inactivated state, NF-𝜅B is bound by
an inhibitor protein, I𝜅B𝛼. In inflammatory conditions,
cell signalling cascades that involve MAP kinases lead to
the phosphorylation of I𝜅B𝛼 [13]. Phosphorylated I𝜅B𝛼 is
targeted for degradation freeing NF-𝜅B to translocate to the
nucleus to active target gene expression that includes VCAM-
1 and ICAM-1. Figure 5(a) shows that TNF-𝛼 significantly
increased NF-𝜅B nuclear activation by 70% (𝑃 < 0.05)
and that pretreatment of HCAECs with HIPER (25 𝜇L/mL)
decreased this effect by 43% (𝑃 < 0.05). Figure 5(b) shows
that the effect of HIPER on suppressing NF-𝜅B activation
was associated with a decrease in phosphorylated I𝜅B𝛼, the
inhibitor protein ofNF-𝜅B. Phosphorylation of I𝜅B𝛼 is driven
by MAP kinase activation. Figures 5(c) and 5(d) show that
HIPER suppressed p38 and MEK1/2 MAP kinases activation
almost to the same basal level as the p38 inhibitor SB203580
or the MEK1/2 inhibitor, UO126. Together, this data suggests
that HIPER suppresses the HCAECs inflammatory response,
at least in part, via suppression of MAP kinase and NF-𝜅B
activation.
3.5. PBE Is Central to the Anti-Inflammatory Effect of HIPER.
To test each HIPER ingredient for an individual anti-
inflammatory effect, HCAECs were exposed to either PBE
(130 𝜇g/mL or 260 𝜇g/mL), aloe vera (1.75mg/mL), honey
(0.1%), or papain (2.4mg/mL) for 3 h before being acti-
vated with TNF-𝛼 (1 ng/mL) for a further 3 h. The anti-
inflammatory effect of each individual component was com-
pared to each other and to the parent compound, HIPER
(25 𝜇L/mL). Figure 6 shows that HIPER (25𝜇L/mL) and PBE
(at both concentrations) decreased TNF-𝛼-induced VCAM-
1 mRNA levels. PBE was twice as effective as HIPER in
decreasing TNF-𝛼-induced VCAM-1 expression (1.5-fold
versus 3-fold, resp., 𝑃 < 0.05). Honey and aloe vera showed
a nonsignificant trend towards decreased VCAM-1 mRNA
levels. By contrast, papain increased VCAM-1 mRNA levels
(1.5-fold, 𝑃 < 0.05) over and above expression levels induced
by TNF-𝛼.
4. Discussion
Extracts from natural substances may have the potential
to complement mainstream medicine. In the present study,
it was shown that HIPER Health Supplement, comprised
of PBE, honey, aloe vera, and papain, decreased TNF-
𝛼-induced ROS levels that was associated with decreased
ICAM-1 and VCAM-1 expression as well as decreased MAP
kinase andNF-𝜅B activation.The physiologic consequence of
the HIPER-mediated suppressed inflammatory response was
decreased monocyte adhesion to HCAECs, which suggests
improved endothelial cell function. Although this project was
solely conducted with an in vitromodel of culturedHCAECs,
the findings suggest that HIPER may have potential to
decrease key early steps in the pathogenesis of atherosclerosis,
specifically the binding of monocytes to coronary artery
endothelial cells.
In this study, we have shown that HIPER, a mix-
ture of PBE, honey, aloe vera, and papain, has significant
anti-inflammatory and antioxidant effects. Pretreatment of
HCAECs to HIPER, at doses in keeping with the recom-
mended daily dosage for human consumption, suppressed
TNF-𝛼-induced MAP kinase and NF-𝜅B activation that, in
turn, decreased ICAM-1 and VCAM-1 expression, thereby
decreasing monocyte adhesion. We further showed that
HIPER suppressed ROS levels in TNF-𝛼-activated HCAECs,
possibly via modulation of key enzymes involved in superox-
ide generation and degradation. Potentially, this antioxidant
property of HIPER may underlie the anti-inflammatory
effects.
Investigation of the individual components showed that
while PBE, honey, and aloe vera were anti-inflammatory,
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Figure 2: HIPER modulated NOX4 and SOD1 mRNA levels in TNF-𝛼-activated HCAECs. HCAECs were treated with HIPER at
concentrations of 6.25, 12.5, 25, and 50 𝜇L/mL for 3 h, before activation with 1 ng/mL TNF-𝛼 for 1 h. Total RNA was extracted and NOX4
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Figure 3: HIPER reduced ICAM-1 and VCAM-1 mRNA and protein levels in TNF-𝛼-activated HCAECs. HCAECs were treated with HIPER
at doses of 6.25, 12.5, 25, and 50 𝜇L/mL for 3 h, before activation with TNF-𝛼 (1 ng/mL) for 1 or 3 h for mRNA or protein levels, respectively.
Total RNA was extracted and ICAM-1 (a) or VCAM-1 (b) mRNA levels were measured by RT-qPCR. Cell-based ELISA was used to measure
ICAM-1 (c) and VCAM-1 (d) protein levels. Data are shown as mean ± SEM (𝑛 = 3). #𝑃 < 0.05 versus control, ∗𝑃 < 0.05 versus TNF-𝛼.























Figure 4: HIPER reducedmonocyte adhesion to TNF-𝛼-activatedHCAECs. HCAECswere treated withHIPER at a dose of 25𝜇L/mL for 3 h,
before activation with TNF-𝛼 (1 ng/mL) for 3 h. HCAECs were then exposed to monocytes (1 × 106 cells/mL) for 1 h after which nonadhered
monocytes were removed and the percentage of adherent monocytes calculated. Data are shown as mean ± SEM (𝑛 = 3). #𝑃 < 0.005 versus


























































































































Figure 5: HIPER reduced NF-𝜅B activation in TNF-𝛼-activated HCAECs. HCAECs were treated with HIPER at a dose of 25𝜇L/mL for 3 h,
before activation with 1 ng/mL TNF-𝛼 for 3 h. For (c) additional cells were treated with SB203580 (10𝜇M) and (d) UO126 (10 𝜇M). For (a)
nuclear extract was obtained and NF-𝜅B levels were measured using commercially available NoShift assay. For (b)–(d), cultured cells were
used directly in commercially available ELISA kits. Data are shown as mean ± SEM (𝑛 = 3) ∗𝑃 < 0.05 versus control, #𝑃 < 0.05 versus TNF-𝛼.





























































Figure 6: Anti-inflammatory effects of individual HIPER compo-
nents.HCAECswere treatedwithHIPERor pine bark extract (PBE),
papain (Pap), honey (Hon), or aloe vera (AV) for 3 h and then
activated with 1 ng/mL TNF-𝛼 for 1 h. Total RNA was extracted and
VCAM-1mRNA levels weremeasured by RT-qPCR. Data are shown
as mean ± SEM (𝑛 = 3). #𝑃 < 0.05 versus control, ∗𝑃 < 0.05 versus
TNF-𝛼, and ∗∗𝑃 < 0.05HIPER versus PBE.
albeit to different extents, papain was proinflammatory. This
is in keeping with its enzymatic role as a peptidase [14].
The use of papain in HIPER, therefore, requires further
investigation as our findings suggest adverse effects that
are potentially decreasing the efficacy of complete HIPER.
On the other hand, PBE was shown to be very effective at
attenuating VCAM-1 mRNA levels. PBE is extracted from
the bark of the French maritime pine tree, Pinus pinaster,
and is commercially available as a herbal dietary supplement
(registered trade name: Pycnogenol). It is already in use
for the treatment of many inflammatory, autoimmune, and
cardiovascular disorders [8, 9, 15–17] and very recently it
was shown to reduce atherosclerotic lesion burden in a small
clinical study [18]. PBE is increasingly recognised for its anti-
inflammatory and antioxidant effects in vitro and in vivo
(reviewed in [9]). For example, in vitro studies have shown
that PBE reduces cell adhesionmolecule expression in human
umbilical vein endothelial cells through suppression of NF-
𝜅B [19], which is in keeping with our current findings for
HIPER that show decreased NF-𝜅B activation and decreased
CAM expression in HCAECs. Similarly, in vitro studies
have demonstrated that PBE reduces ROS levels in renal
tubular cells in association with decreased lipid peroxidation
[20], again in accordance with our data for HIPER showing
decreased ROS levels in HCAECs. In vivo, a recent ran-
domized, double-blind, placebo-controlled crossover showed
that 8 weeks of Pycnogenol treatment (200mg/day) improves
endothelial function in patients with coronary artery disease
by reducing oxidative stress [21]. Therefore, it would now be
prudent not only to test whether HIPER is able to recapitulate
its in vitro effects when administered in vivo but also to test
whether synergistic actions between PBE, honey, and aloe
vera occur in vivo.
Limitations of our study include the facts that that it is an
in vitro investigation and the bioavailability and/or bioacti-
vation of HIPER and its components were not investigated.
In this study HCAECs were directly treated with the HIPER
to investigate the effects. However, in vivo, HIPER would
be digested and metabolized by the liver that may generate
metabolites that provide further or no benefit. Therefore,
effects of directHIPER exposure onHCAECsmay differ from
the effects when HCAECs are exposed to the metabolites of
HIPER.
In conclusion, our results demonstrate the anti-
inflammatory and antioxidant potential of HIPER containing
the natural products, PBE, honey, aloe vera, and papain. Our
finding that HIPER has a potent ability to decrease NF-𝜅B
andMAP kinase activation, and therefore inflammatory gene
expression, suggests that HIPER could be beneficial against
a number of inflammatory conditions where cell adhesion
molecules and monocyte adhesion are an underlying
pathogenic mechanism that includes atherosclerosis.
Endothelial cell dysfunction resulting in the local recruitment
of leukocytes to sites of inflammatory challenge is a crucial
step in the initiation of the atherosclerotic process, as well as
the development of advanced atherosclerosis [22]. Therefore,
it would be worth investigating further the effects of HIPER
on suppressing early atherosclerotic lesion formation in an
in vivomodel.
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